AG
MRKR icon

Advisor Group’s Marker Therapeutics MRKR Stock Holding History

Advisor Group’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2
Closed – – 5393
2019
Q3 		$0 Hold
2
– – ﹤0.01% 5368
2019
Q2 		$0 Hold
2
– – ﹤0.01% 5310
2019
Q1 		$0 Hold
2
– – ﹤0.01% 5275
2018
Q4 		$0 Sell
2
-26
-93% -$1.9K ﹤0.01% 5178
2018
Q3 		$3K Hold
28
– – ﹤0.01% 4753
2018
Q2 		$3K Hold
28
– – ﹤0.01% 4558
2018
Q1 		$1K Hold
28
– – ﹤0.01% 4829
2017
Q4 		$1K Hold
28
– – ﹤0.01% 4836
2017
Q3 		$1K Hold
28
– – ﹤0.01% 4693
2017
Q2 		$1K Hold
28
– – ﹤0.01% 4641
2017
Q1 		$1K Hold
28
– – ﹤0.01% 4548
2016
Q4 		$1K Buy
+28
New +$1.3K ﹤0.01% 4372

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Advisor Group's MRKR Position: Q4 2019 in Review

Advisor Group sold out of Marker Therapeutics (MRKR) in Q4 2019, closing a stake of 2 shares.

Advisor Group first reported a position in MRKR in Q4 2016 and held it in 12 quarters. The position peaked at $3K in Q3 2018. 65 funds tracked by Wall St. Rank hold MRKR as of Q4 2019.

  • Advisor Group reported no remaining Marker Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Advisor Group sold 2 Marker Therapeutics shares in Q4 2019.
  • Advisor Group first reported a position in Marker Therapeutics in Q4 2016 and held it in 12 quarters.
  • Advisor Group's Marker Therapeutics position peaked at $3K in Q3 2018.
  • 65 funds tracked by Wall St. Rank held Marker Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.